SCPH
Price
$4.47
Change
+$0.39 (+9.56%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
215.39M
26 days until earnings call
TRVI
Price
$6.40
Change
+$0.23 (+3.73%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
751.23M
27 days until earnings call
Interact to see
Advertisement

SCPH vs TRVI

Header iconSCPH vs TRVI Comparison
Open Charts SCPH vs TRVIBanner chart's image
scPharmaceuticals
Price$4.47
Change+$0.39 (+9.56%)
Volume$7.44K
Capitalization215.39M
Trevi Therapeutics
Price$6.40
Change+$0.23 (+3.73%)
Volume$32.36K
Capitalization751.23M
SCPH vs TRVI Comparison Chart in %
Loading...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCPH vs. TRVI commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCPH is a StrongBuy and TRVI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (SCPH: $4.47 vs. TRVI: $6.17)
Brand notoriety: SCPH and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCPH: 154% vs. TRVI: 86%
Market capitalization -- SCPH: $215.39M vs. TRVI: $751.23M
SCPH [@Biotechnology] is valued at $215.39M. TRVI’s [@Biotechnology] market capitalization is $751.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCPH’s FA Score shows that 0 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • SCPH’s FA Score: 0 green, 5 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, both SCPH and TRVI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCPH’s TA Score shows that 4 TA indicator(s) are bullish while TRVI’s TA Score has 4 bullish TA indicator(s).

  • SCPH’s TA Score: 4 bullish, 4 bearish.
  • TRVI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than TRVI.

Price Growth

SCPH (@Biotechnology) experienced а +12.59% price change this week, while TRVI (@Biotechnology) price change was +3.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

SCPH is expected to report earnings on Nov 05, 2025.

TRVI is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TRVI($751M) has a higher market cap than SCPH($215M). TRVI YTD gains are higher at: 55.583 vs. SCPH (26.271). TRVI has higher annual earnings (EBITDA): -47.23M vs. SCPH (-83.9M). TRVI has more cash in the bank: 103M vs. SCPH (57.5M). TRVI has less debt than SCPH: TRVI (957K) vs SCPH (52.4M). SCPH has higher revenues than TRVI: SCPH (42M) vs TRVI (0).
SCPHTRVISCPH / TRVI
Capitalization215M751M29%
EBITDA-83.9M-47.23M178%
Gain YTD26.27155.58347%
P/E RatioN/AN/A-
Revenue42M0-
Total Cash57.5M103M56%
Total Debt52.4M957K5,475%
FUNDAMENTALS RATINGS
SCPH vs TRVI: Fundamental Ratings
SCPH
TRVI
OUTLOOK RATING
1..100
6356
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4243
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (57) in the Pharmaceuticals Major industry is in the same range as SCPH (60). This means that TRVI’s stock grew similarly to SCPH’s over the last 12 months.

TRVI's Profit vs Risk Rating (75) in the Pharmaceuticals Major industry is in the same range as SCPH (100). This means that TRVI’s stock grew similarly to SCPH’s over the last 12 months.

TRVI's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as SCPH (100). This means that TRVI’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as TRVI (43). This means that SCPH’s stock grew similarly to TRVI’s over the last 12 months.

SCPH's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as TRVI (100). This means that SCPH’s stock grew similarly to TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCPHTRVI
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NSGAX22.40N/A
N/A
Columbia Select Large Cap Equity A
LCORX22.70N/A
N/A
Leuthold Core Investment Retail
HRAUX84.42N/A
N/A
Carillon Eagle Mid Cap Growth R6
MGFRX9.56N/A
N/A
MassMutual Global R4
RPNIX10.75N/A
N/A
Riverpark/Next Century Gr Inst

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
+9.56%
CRSP - SCPH
46%
Loosely correlated
-1.80%
BEAM - SCPH
45%
Loosely correlated
+2.66%
AURA - SCPH
44%
Loosely correlated
+2.73%
YMAB - SCPH
44%
Loosely correlated
+1.80%
AVIR - SCPH
43%
Loosely correlated
+0.53%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+3.89%
PTGX - TRVI
43%
Loosely correlated
+1.02%
BIESF - TRVI
43%
Loosely correlated
N/A
GOSS - TRVI
33%
Loosely correlated
N/A
MLYS - TRVI
31%
Poorly correlated
+1.88%
QURE - TRVI
30%
Poorly correlated
+0.07%
More